APP and Alzheimer disease: Cholesterol reducing drugs such as statin decrease brain Aβ level and increase non-amyloidogenic α -secretase cleavage of amyloid precursor protein and lead in reduced Aβ deposition.[7][8][9][10] High cholesterol diet in transgenic animal models of AD leads in increased Aβ deposition in the brain.[8][11][12] On the other hand, it was shown that the prevalence of AD is 60%-70% lower in cholesterol reducing drug consumers.[1][13][14] Thus the risk of AD and Aβ deposition can be altered by factors associated with cholesterol level.